OV acquires three DRP’s for potential new drug candidates

Hoersholm, Denmark; April 27th, 2016 – Oncology Venture Sweden AB (OV:ST) announces the acquisition of three new DRP’s from Medical Prognosis Institute for three new selected, undisclosed anti-cancer drug candidates. OV have now secured a total of ten DRP’s. Three of these are the DRP’s for Irofulven, LiPlaCis and APO010. Using the DRP™ platform, OV intends to enhance the chances of achieving authority approval on its drugs in the pipeline.

Prior to acquiring the DRP’s the OV team of hematology and oncology experts have evaluated the anti-cancer drug on official available material and documentation. Having secured the DRP’s the next step in the process is negotiations and due diligence processes with the companies in question, and eventually a product might be inlicensed.

“I’m very excited to say we are now expanding our portfolio with another three DRP’s. We see great potential in having secured these DRP’s as the drug candidates could become approved future products for doctors and patients to benefit from in successfully treating cancer. Our belief is that the DRP™ platform will provide the right assistance to reach the clinical success levels required for authority approval. This is another important step on our path of developing more effective treatment for cancer patients”, says Adjunct Professor Peter Buhl Jensen, M.D., PhD and CEO of Oncology Venture.

About the Drug Response Predictor DRP™ Screening Tool

Oncology Venture uses Medical Prognosis’ DRP™ Screening Tool to select patients who by the gene signature of their cancer have a high likelihood to respond to a certain drug. The goal is to develop the drug for the right patients, and by screening patients before treatment the response rate can be significantly increased.

The DRP™ method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The microRNA based DRP™ is used on certain products where the DRP™ based on messenger RNA is more broadly useful and more validated.

For further information, please contact

Ulla Hald Buhl, COO and Chief IR & CommunicationsMobile: +45 2170 1049uhb@oncologyventure.com or Peter Buhl Jensen, CEOMobile: +45 21 60 89 22E-mail: pbj@oncologyventure.com

About Oncology Venture Sweden AB

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that betters the odds compared to traditional pharmaceutical development. Instead of treating all patients suffering from a particular type of cancer, patients are first screened, and only those most likely to respond to the treatment will be treated. With a more defined patient group, risks and costs are reduced, and the process of drug development becomes more efficient.

Our current product portfolio: LiPlaCis, an intelligent liposomal formulation of cisplatin for Breast Cancer, Irofulven, developed from a fungus, for Prostate Cancer, and APO010, an immuno-oncology product for Multiple Myeloma.


Documents & Links